{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:21:08Z","timestamp":1787235668168,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.clinthera.2013.12.002","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T12:01:05Z","timestamp":1388750465000},"page":"101-114","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct00964262","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Namyi","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Heon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaeWoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongseong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeyong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1016\/j.clinthera.2013.12.002_bib1","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.amjmed.2010.11.003","article-title":"Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?","volume":"124","author":"Zinman","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.12.002_bib2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2013.12.002_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clinthera.2013.12.002_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2013.12.002_bib5","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2013.12.002_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2013.12.002_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbrc.2009.10.054","article-title":"Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents","volume":"390","author":"Arakawa","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2013.12.002_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2337\/diabetes.54.2.482","article-title":"beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1","volume":"54","author":"Li","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2013.12.002_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.12.002_bib10","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.12.002_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.12.002_bib12","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.12.002_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/VHRM.S28744","article-title":"Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis","volume":"8","author":"Gaebler","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2013.12.002_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/pr.110.003319","article-title":"Novel pharmacological approaches to the treatment of type 2 diabetes","volume":"64","author":"Verspohl","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2013.12.002_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2013.12.002_bib16","unstructured":"Ethical Principles for Medical Research Involving Human Subjects, 59th WMA General Assembly, Seoul 2008. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/17c.pdf. Accessed November 4, 2011."},{"key":"10.1016\/j.clinthera.2013.12.002_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u201cideal\u201d body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2013.12.002_bib18","unstructured":"US Food Drug Administration. Guidance for Industry, Bioanalytical Method Validation. Washington, DC: US Food and Drug Administration, Center for Drug Evaluation and Research; 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm070107.pdf. Accessed November 4, 2011."},{"key":"10.1016\/j.clinthera.2013.12.002_bib19","series-title":"Pharmacokokinetic-Pharmacodynamic Modelling and Simulation","author":"Bonate","year":"2011"},{"key":"10.1016\/j.clinthera.2013.12.002_bib20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0026-0495(03)00327-5","article-title":"Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects","volume":"52","author":"Meier","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2013.12.002_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ageing\/afm076","article-title":"Oral glucose tolerance test in the assessment of glucose-tolerance in the elderly people","volume":"36","author":"Stevic","year":"2007","journal-title":"Age Ageing"},{"key":"10.1016\/j.clinthera.2013.12.002_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2013.12.002_bib23","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s00592-010-0194-4","article-title":"Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese","volume":"49","author":"Bi","year":"2012","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2013.12.002_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI105534","article-title":"Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus","volume":"46","author":"Seltzer","year":"1967","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.12.002_bib25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.12.002_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.jhh.1002201","article-title":"Validity and reproducibility of HOMA-IR, 1\/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes","volume":"21","author":"Sarafidis","year":"2007","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2013.12.002_bib27","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2013.12.002_bib28","doi-asserted-by":"crossref","first-page":"291027","DOI":"10.1155\/2009\/291027","article-title":"Positive correlation of PTH-related peptide with glucose in type 2 diabetes","volume":"2009","author":"Legakis","year":"2009","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.clinthera.2013.12.002_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"DeYoung","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2013.12.002_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-3155-9-55","article-title":"Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines","volume":"9","author":"Mahapatro","year":"2011","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.clinthera.2013.12.002_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2013.12.002_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","article-title":"Exenatide: a review from pharmacology to clinical practice","volume":"11","author":"Gentilella","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2013.12.002_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11585880-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing","volume":"50","author":"Fineman","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2013.12.002_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/clpt.2009.159","article-title":"Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects","volume":"86","author":"Steinert","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.12.002_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/EJE-13-0264","article-title":"Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty","volume":"169","author":"Plamboeck","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2013.12.002_bib36","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1210\/jc.2012-3971","article-title":"Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired beta-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study","volume":"98","author":"Bianchi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2013.12.002_bib37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1464-5491.2009.02854.x","article-title":"Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with type 2 diabetes","volume":"26","author":"Kapitza","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2013.12.002_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/dc11-1942","article-title":"Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)","volume":"35","author":"Raz","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T16:12:45Z","timestamp":1565021565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813011107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0149291813011107"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.12.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}